Codexis Inc (CDXS) Stock Price, Quote & News

Company Profile

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 421 8100

Website: www.codexis.com

Address:

200 Penobscot Drive, Redwood City, United States

10xMoonstocks May. 13 at 9:13 PM

$CDXS I love the potential here, but I think we see under $2.20 again, assuming we dont get any announcements. Market seems to have soured here in the short term

1 · Reply

nlstbro May. 13 at 4:38 PM

$CDXS

0 · Reply

Fingerlickengood May. 13 at 3:35 PM

$CDXS https://informaconnect.com/tides/oligonucleotide-chemistry-manufacturing-controls/

1 · Reply

Rolbox May. 13 at 2:21 PM

$CDXS

0 · Reply

nlstbro May. 13 at 2:16 PM

$CDXS

0 · Reply

Camille65 May. 13 at 10:46 AM

$CDXS Buy the dip. This is $10 stock (at least). 2026 guidance bound to be raised. Still low valuation EV/Sales and also in comparison to other CDMO.

1 · Reply

Catmando3 May. 12 at 9:02 PM

$CDXS another catalysts on the horizon?

0 · Reply

djohndjohn May. 12 at 9:01 PM

$CDXS After the March earnings call the SP went down 4 days before starting the climb into the mid $2 area:-)

0 · Reply

Jiggitus23 May. 12 at 3:09 PM

$CDXS this is going to get boring for a while isn't it.

2 · Reply

Fingerlickengood May. 12 at 11:35 AM

$CDXS You are absolutely correct! https://www.globenewswire.com/news-release/2019/02/04/1710176/24825/en/codexis-secures-multi-year-technology-upgrade-package-for-its-codeevolver-protein-engineering-platform-license-with-merck.html

0 · Reply

Codexis reports Q1 EPS (10c), consensus (10c)

2026-05-07T22:51:14.000Z - 6 days ago

Codexis backs FY26 revenue view $72M-$76M, consensus $74.24M

May 7, 2026, 4:30 PM EDT - 6 days ago

Codexis Earnings Call Transcript: Q1 2026

May 7, 2026, 4:05 PM EDT - 6 days ago

Codexis Reports First Quarter 2026 Financial Results

Apr 29, 2026, 9:00 AM EDT - 14 days ago

Codexis to share RNA manufacturing advances at TIDES USA

Mar 11, 2026, 4:30 PM EDT - 2 months ago

Codexis Earnings Call Transcript: Q4 2025

2026-03-11T20:25:25.000Z - 2 months ago

Codexis reports Q4 EPS 11c, consensus (4c)

2026-03-11T20:25:07.000Z - 2 months ago

Codexis sees FY26 revenue $72M-$76M, consensus $70.8M

Mar 11, 2026, 4:05 PM EDT - 2 months ago

Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

2026-03-04T15:11:46.000Z - 2 months ago

Codexis announces agreement to manufacture 50 g siRNA

Mar 4, 2026, 10:06 AM EST - 2 months ago

Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform

Mar 3, 2026, 11:50 AM EST - 2 months ago

Codexis Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 9:00 AM EST - 2 months ago

Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11

2026-02-10T14:05:57.000Z - 3 months ago

Codexis achieves ISO 9001:2015 certification

Feb 10, 2026, 9:00 AM EST - 3 months ago

Codexis Achieves ISO 9001:2015 Certification

2026-01-07T14:12:08.000Z - 4 months ago

Codexis signs evaluation agreement with Axolabs

Jan 7, 2026, 9:00 AM EST - 4 months ago

Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics

2025-11-10T14:11:19.000Z - 6 months ago

Codexis announces signing of lease for GMP manufacturing facility

Nov 10, 2025, 9:00 AM EST - 6 months ago

Codexis Announces Signing of Lease for GMP Manufacturing Facility

2025-11-06T22:35:34.000Z - 6 months ago

Codexis reports Q3 EPS (22c), consensus (13c)

Nov 6, 2025, 4:30 PM EST - 6 months ago

Codexis Earnings Call Transcript: Q3 2025

2025-10-29T14:05:32.000Z - 7 months ago

Codexis, Nitto Denko Avecia enter evaluation agreement

Oct 29, 2025, 9:58 AM EDT - 7 months ago

Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing

Oct 23, 2025, 7:05 AM EDT - 7 months ago

Codexis to Report Third Quarter 2025 Financial Results on November 6

Sep 4, 2025, 3:55 PM EDT - 8 months ago

Codexis Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 9:00 AM EDT - 9 months ago

Codexis to Participate in Cantor Global Healthcare Conference

Aug 13, 2025, 4:30 PM EDT - 9 months ago

Codexis Earnings Call Transcript: Q2 2025

Aug 13, 2025, 4:05 PM EDT - 9 months ago

Codexis Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 10 months ago

Codexis to Report Second Quarter 2025 Financial Results on August 13

Jun 4, 2025, 3:10 PM EDT - 1 year ago

Codexis Transcript: Jefferies Global Healthcare Conference 2025

May 22, 2025, 8:00 AM EDT - 1 year ago

Codexis Transcript: Status Update

2025-05-22T11:10:44.000Z - 1 year ago

Codexis presents data on ECO Synthesis platform at TIDES USA meeting

May 22, 2025, 7:00 AM EDT - 1 year ago

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

May 21, 2025, 4:05 PM EDT - 1 year ago

Codexis to Participate in Jefferies Global Healthcare Conference

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q1 2025

2025-05-14T20:16:47.000Z - 1 year ago

Codexis reports Q1 EPS (25c), consensus (21c)

2025-05-14T20:16:39.000Z - 1 year ago

Codexis sees FY25 revenue $64M-$68M, consensus $65.67M

May 14, 2025, 4:05 PM EDT - 1 year ago

Codexis Reports First Quarter 2025 Financial Results

May 7, 2025, 7:00 AM EDT - 1 year ago

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Codexis to Report First Quarter 2025 Financial Results on May 14

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Codexis Announces Byron Dorgan to Retire from Board of Directors

2025-04-01T11:21:28.000Z - 1 year ago

Codexis appoints Cynthia Collins to board of directors

2025-03-25T19:37:37.000Z - 1 year ago

Investors should buy Codexis following contract news, says Craig-Hallum

ALNY DHR

2025-03-24T11:20:13.000Z - 1 year ago

Codexis announces first revenue-generating contract for ECO Synthesis services

Mar 7, 2025, 4:05 PM EST - 1 year ago

Codexis Announces New Employment Inducement Grants

Mar 4, 2025, 1:10 PM EST - 1 year ago

Codexis Transcript: TD Cowen 45th Annual Healthcare Conference

2025-02-27T22:00:31.000Z - 1 year ago

Codexis reports Q4 EPS (13c), consensus (2c)

2025-02-27T22:00:23.000Z - 1 year ago

Codexis sees FY25 revenue $64M-$68M, consensus $66.61M

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Earnings Call Transcript: Q4 2024

Feb 13, 2025, 4:05 PM EST - 1 year ago

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Feb 6, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Jan 16, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Christos Richards to Board of Directors

Dec 3, 2024, 11:00 AM EST - 1 year ago

Codexis Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 1:00 PM EST - 1 year ago

Codexis Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 19, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 4:30 AM EST - 1 year ago

Codexis Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 2:25 PM EST - 1 year ago

Codexis Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Codexis Transcript: Status Update

Nov 14, 2024, 4:05 PM EST - 1 year ago

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Nov 12, 2024, 4:05 PM EST - 1 year ago

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Nov 11, 2024, 4:05 PM EST - 1 year ago

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Nov 4, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Upcoming Healthcare Conferences

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q3 2024

Oct 24, 2024, 4:05 PM EDT - 1 year ago

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Third Quarter 2024 Financial Results on October 31

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Oct 1, 2024, 7:05 AM EDT - 1 year ago

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Sep 17, 2024, 11:30 AM EDT - 1 year ago

Codexis Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Codexis Publishes FY2023 Sustainability Disclosures

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q2 2024

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Second Quarter 2024 Financial Results on August 8

Jul 1, 2024, 4:05 PM EDT - 2 years ago

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

Jun 5, 2024, 11:30 AM EDT - 2 years ago

Codexis Transcript: Jefferies Global Healthcare Conference

May 20, 2024, 4:05 PM EDT - 2 years ago

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

May 14, 2024, 6:00 AM EDT - 2 years ago

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings Call Transcript: Q1 2024

Apr 18, 2024, 4:05 PM EDT - 2 years ago

Codexis to Report First Quarter 2024 Financial Results on May 2

Apr 11, 2024, 7:05 AM EDT - 2 years ago

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Mar 4, 2024, 2:50 PM EST - 2 years ago

Codexis Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Earnings Call Transcript: Q4 2023

Feb 28, 2024, 4:05 PM EST - 2 years ago

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Feb 26, 2024, 8:05 AM EST - 2 years ago

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Feb 20, 2024, 8:05 AM EST - 2 years ago

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Feb 14, 2024, 4:05 PM EST - 2 years ago

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Feb 13, 2024, 4:05 PM EST - 2 years ago

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

Feb 1, 2024, 4:05 PM EST - 2 years ago

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Dec 27, 2023, 8:30 AM EST - 2 years ago

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Dec 13, 2023, 4:06 PM EST - 2 years ago

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Dec 13, 2023, 4:05 PM EST - 2 years ago

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

10xMoonstocks May. 13 at 9:13 PM

$CDXS I love the potential here, but I think we see under $2.20 again, assuming we dont get any announcements. Market seems to have soured here in the short term

1 · Reply

nlstbro May. 13 at 4:38 PM

$CDXS

0 · Reply

Fingerlickengood May. 13 at 3:35 PM

$CDXS https://informaconnect.com/tides/oligonucleotide-chemistry-manufacturing-controls/

1 · Reply

Rolbox May. 13 at 2:21 PM

$CDXS

0 · Reply

nlstbro May. 13 at 2:16 PM

$CDXS

0 · Reply

Camille65 May. 13 at 10:46 AM

$CDXS Buy the dip. This is $10 stock (at least). 2026 guidance bound to be raised. Still low valuation EV/Sales and also in comparison to other CDMO.

1 · Reply

Catmando3 May. 12 at 9:02 PM

$CDXS another catalysts on the horizon?

0 · Reply

djohndjohn May. 12 at 9:01 PM

$CDXS After the March earnings call the SP went down 4 days before starting the climb into the mid $2 area:-)

0 · Reply

Jiggitus23 May. 12 at 3:09 PM

$CDXS this is going to get boring for a while isn't it.

2 · Reply

Fingerlickengood May. 12 at 11:35 AM

0 · Reply

Fingerlickengood May. 12 at 11:26 AM

$CDXS $MRK ”Using ATP-dependent ligases and transacylation by a hydrolase, the authors assembled a large fragment containing the first macrolactam ring. They then combined this fragment with two chemically synthesized fragments in a five-enzyme cascade and a chemoenzymatic step. The resulting synthesis is exceptionally efficient, avoids protecting groups, and is optimized for multikilogram-scale production with an overall yield of around 40%. ”

0 · Reply

Fingerlickengood May. 12 at 11:16 AM

$CDXS Shorts continue to return shares on a day-day basis! From 10 million shares held short a month ago to under 5 million as of this am! Buying hand over fist while the stock price remains artificially deflated.

0 · Reply

Hertha May. 12 at 12:22 AM

$CDXS Enlicitide is exactly the kind of complex therapeutic where Codexis’ enzyme-engineering platform matters. At their current scale, confirmation will be 🚀 https://www.msd.com/news/msd-scientists-publish-landmark-paper-on-novel-method-for-large-scale-biocatalytic-synthesis-of-investigational-oral-pcsk9-inhibitor-enlicitide-decanoate/

0 · Reply

Fingerlickengood May. 11 at 5:03 PM

$CDXS $MRK What are the chances Codexis was a part of this?! "Merck scientists detail the biocatalytic assembly of enlicitide using a suite of enzymes that catalyze selective peptide fragment formation, coupling, and macrocyclization. Together with efficient purifications using crystallization, this strategy enabled the manufacture of a product that would not be possible with traditional synthetic methods. The method described offers a sustainable blueprint for the scalable development of complex macrocyclic peptide therapeutics, environmental advantages and manufacturing efficiencies that support efforts to expand patient access."

0 · Reply

Fingerlickengood May. 11 at 5:00 PM

$CDXS $MRK Interesting! https://www.nasdaq.com/press-release/merck-scientists-publish-landmark-paper-novel-method-large-scale-biocatalytic

0 · Reply

Fingerlickengood May. 11 at 2:22 PM

$CDXS https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdxs/codexis/news/us658-thats-what-analysts-think-codexis-inc-nasdaqcdxs-is-wo/amp

0 · Reply

nlstbro May. 11 at 1:57 PM

$CDXS

0 · Reply

Fingerlickengood May. 11 at 1:51 PM

$CDXS

0 · Reply

Fingerlickengood May. 11 at 12:42 PM

$CDXS $NVS Especially after considering Codexis’ existing partnerships in India for enzymatic drug manufacturing! https://www.globenewswire.com/news-release/2021/10/18/2315614/24825/en/codexis-almelo-and-rc2-announce-a-tri-party-collaboration-for-the-enzymatic-production-of-low-cost-sitagliptin-api-for-the-generic-market-including-a-license-to-codexis-enzyme-tech.html

1 · Reply

Fingerlickengood May. 11 at 12:37 PM

$CDXS $NVS Lots of potential here! “India played a major role in several global therapies, including Coartem Baby, cardiovascular drug Inclisiran (Sybrava), and prostate cancer therapy Pluvicto. Our philosophy has been to transform into a pure-play innovative medicines company,” Dube told TOI, adding that Novartis remains committed to India with over 9,000 employees and plans to launch more new molecules in the coming years.“ https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/novartis-expands-india-role-in-global-drug-development/amp_articleshow/131009829.cms

0 · Reply

djohndjohn May. 10 at 11:30 AM

$CDXS Stereochemistry in RNAi Manufacturing is Big!

0 · Reply

Market Cap	240.88M
Revenue (ttm)	70.39M
Net Income (ttm)	-43.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-62.47%
Debt to Equity Ratio	0.94

Volume	915,600
Avg Vol	2,626,766
Day's Range	N/A - N/A
Shares Out	90.90M
Stochastic %K	6%
Beta	2.52
Analysts	Strong Sell
Price Target	$6.58